• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

孕激素受体免疫组化表达的定量测量以预测子宫内膜癌的淋巴结转移

Quantitative Measurement of Progesterone Receptor Immunohistochemical Expression to Predict Lymph Node Metastasis in Endometrial Cancer.

作者信息

Hsiao Yu-Yang, Fu Hung-Chun, Wu Chen-Hsuan, Lan Jui, Ou Yu-Che, Tsai Ching-Chou, Lin Hao

机构信息

Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 83341, Taiwan.

Department of Obstetrics and Gynecology, Chia-Yi Chang Gung Memorial Hospital, Chia-Yi 61363, Taiwan.

出版信息

Diagnostics (Basel). 2022 Mar 23;12(4):790. doi: 10.3390/diagnostics12040790.

DOI:10.3390/diagnostics12040790
PMID:35453837
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9031886/
Abstract

Background: Previous studies have shown that loss of progesterone receptor (PR) in endometrial cancer (EC) is associated with poor outcomes. Evaluating lymph node metastasis (LNM) is essential, especially before surgical staging. The aim of this study was to investigate the role of PR expression and other clinicopathological parameters in LNM and to develop a prediction model. Methods: We retrospectively evaluated endometrioid-type EC patients treated with staging surgery between January 2015 and March 2020. We analyzed PR status using immunohistochemical staining, and the expression was quantified using the H-score. We identified optimal cut-off values of H-score and CA125 for predicting LNM using receiver operating characteristic curves, and used stepwise multivariate logistic regression analysis to identify independent predictors. A nomogram for predicting LNM was constructed and validated using bootstrap resampling. Results: Of the 310 patients evaluated, the optimal cut-off values of PR H-score and CA125 were 162.5 (AUC 0.670, p = 0.001) and 40 U/mL (AUC 0.739, p < 0.001), respectively. Multivariate analysis showed that CA125 ≥ 40 U/mL (OR: 8.03; 95% CI: 3.44−18.77), PR H-score < 162.5 (OR: 5.22; 95% CI: 1.87−14.60), and tumor grade 2/3 (OR: 3.25; 95% CI: 1.33−7.91) were independent predictors. These three variables were incorporated into a nomogram, which showed effective discrimination with a concordance index of 0.829. Calibration curves for the probability of LNM showed optimal agreement between the probability as predicted by the nomogram and the actual probability. Our model gave a negative predictive value and a negative likelihood ratio of 98.4% and 0.14, respectively. Conclusions: PR H-score along with tumor grade and CA125 are helpful to predict LNM. In addition, our nomogram can aid in decision making with regard to lymphadenectomy in endometrioid-type EC.

摘要

背景

既往研究表明,子宫内膜癌(EC)中孕激素受体(PR)缺失与预后不良相关。评估淋巴结转移(LNM)至关重要,尤其是在手术分期之前。本研究的目的是探讨PR表达及其他临床病理参数在LNM中的作用,并建立一个预测模型。方法:我们回顾性评估了2015年1月至2020年3月期间接受分期手术治疗的子宫内膜样型EC患者。我们采用免疫组织化学染色分析PR状态,并使用H评分对表达进行量化。我们使用受试者工作特征曲线确定预测LNM的H评分和CA125的最佳截断值,并使用逐步多因素逻辑回归分析确定独立预测因素。构建了一个预测LNM的列线图,并使用自助重抽样进行验证。结果:在评估的310例患者中,PR H评分和CA125的最佳截断值分别为162.5(AUC 0.670,p = 0.001)和40 U/mL(AUC 0.739,p < 0.001)。多因素分析显示,CA125≥40 U/mL(OR:8.03;95%CI:3.44−18.77)、PR H评分<162.5(OR:5.22;95%CI:1.87−14.60)和肿瘤分级2/3(OR:3.25;95%CI:1.33−7.91)是独立预测因素。这三个变量被纳入一个列线图,该列线图显示出有效的区分能力,一致性指数为0.829。LNM概率的校准曲线显示,列线图预测的概率与实际概率之间具有最佳一致性。我们的模型的阴性预测值和阴性似然比分别为98.4%和0.14。结论:PR H评分以及肿瘤分级和CA125有助于预测LNM。此外,我们的列线图可辅助子宫内膜样型EC患者淋巴结切除术的决策制定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605d/9031886/171e57f5482f/diagnostics-12-00790-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605d/9031886/05d135e3977f/diagnostics-12-00790-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605d/9031886/2cd14024a240/diagnostics-12-00790-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605d/9031886/35ad16f69328/diagnostics-12-00790-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605d/9031886/171e57f5482f/diagnostics-12-00790-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605d/9031886/05d135e3977f/diagnostics-12-00790-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605d/9031886/2cd14024a240/diagnostics-12-00790-g002a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605d/9031886/35ad16f69328/diagnostics-12-00790-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605d/9031886/171e57f5482f/diagnostics-12-00790-g004.jpg

相似文献

1
Quantitative Measurement of Progesterone Receptor Immunohistochemical Expression to Predict Lymph Node Metastasis in Endometrial Cancer.孕激素受体免疫组化表达的定量测量以预测子宫内膜癌的淋巴结转移
Diagnostics (Basel). 2022 Mar 23;12(4):790. doi: 10.3390/diagnostics12040790.
2
Estrogen/Progesterone Receptor Expression and Cancer Antigen 125 Level as Preoperative Predictors to Estimate Lymph Node Metastasis in Endometrioid Endometrial Cancer.雌激素/孕激素受体表达和癌抗原 125 水平作为术前预测指标,用于评估子宫内膜样型子宫内膜癌的淋巴结转移。
Int J Gynecol Pathol. 2024 Jul 1;43(4):316-325. doi: 10.1097/PGP.0000000000000984. Epub 2023 Sep 8.
3
Pretreatment carcinoembryonic antigen combined with cancer antigen-125 for predicting lymph node metastasis in endometrial carcinoma: a retrospective cohort study.术前癌胚抗原联合癌抗原 125 预测子宫内膜癌淋巴结转移:一项回顾性队列研究。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11807-11813. doi: 10.1007/s00432-023-05087-1. Epub 2023 Jul 5.
4
Predicting Lymph Node Metastasis in Endometrial Cancer Using Serum CA125 Combined with Immunohistochemical Markers PR and Ki67, and a Comparison with Other Prediction Models.利用血清CA125联合免疫组化标志物PR和Ki67预测子宫内膜癌的淋巴结转移,并与其他预测模型进行比较。
PLoS One. 2016 May 10;11(5):e0155145. doi: 10.1371/journal.pone.0155145. eCollection 2016.
5
Combining Clinicopathological Parameters and Molecular Indicators to Predict Lymph Node Metastasis in Endometrioid Type Endometrial Adenocarcinoma.结合临床病理参数和分子指标预测子宫内膜样型子宫内膜腺癌的淋巴结转移
Front Oncol. 2021 Aug 4;11:682925. doi: 10.3389/fonc.2021.682925. eCollection 2021.
6
A nomogram prediction model for lymph node metastasis in endometrial cancer patients.用于预测子宫内膜癌患者淋巴结转移的列线图预测模型。
BMC Cancer. 2021 Jun 29;21(1):748. doi: 10.1186/s12885-021-08466-4.
7
A nomogram for predicting lymph node metastasis in surgically resected T1 esophageal squamous cell carcinoma.预测手术切除的T1期食管鳞状细胞癌淋巴结转移的列线图。
J Thorac Dis. 2018 Jul;10(7):4178-4185. doi: 10.21037/jtd.2018.06.51.
8
Development of a novel predictive model for lymph node metastasis in patients with endometrial endometrioid carcinoma.开发一种用于预测子宫内膜样型癌患者淋巴结转移的新型预测模型。
BMC Cancer. 2022 Dec 20;22(1):1333. doi: 10.1186/s12885-022-10437-2.
9
Analysis of Factors Related to Lymph Node Metastasis in Early-Stage Type 1 Endometrial Cancer: Verifying the Clinical Value of Positive Threshold of the Immunohistochemical Parameter Ki67.早期1型子宫内膜癌淋巴结转移相关因素分析:验证免疫组化参数Ki67阳性阈值的临床价值
Cancer Manag Res. 2021 Aug 10;13:6319-6328. doi: 10.2147/CMAR.S316211. eCollection 2021.
10
The preoperative serum CA125 can predict the lymph node metastasis in endometrioid-type endometrial cancer.术前血清CA125可预测子宫内膜样型子宫内膜癌的淋巴结转移。
Ginekol Pol. 2018;89(11):599-606. doi: 10.5603/GP.a2018.0103.

引用本文的文献

1
The value of machine learning in preoperative identification of lymph node metastasis status in endometrial cancer: a systematic review and meta-analysis.机器学习在子宫内膜癌术前淋巴结转移状态识别中的价值:一项系统评价和荟萃分析
Front Oncol. 2023 Dec 20;13:1289050. doi: 10.3389/fonc.2023.1289050. eCollection 2023.
2
Pretreatment carcinoembryonic antigen combined with cancer antigen-125 for predicting lymph node metastasis in endometrial carcinoma: a retrospective cohort study.术前癌胚抗原联合癌抗原 125 预测子宫内膜癌淋巴结转移:一项回顾性队列研究。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11807-11813. doi: 10.1007/s00432-023-05087-1. Epub 2023 Jul 5.

本文引用的文献

1
Lymphadenectomy issues in endometrial cancer.子宫内膜癌的淋巴结切除术问题。
J Gynecol Oncol. 2021 Mar;32(2):e25. doi: 10.3802/jgo.2021.32.e25. Epub 2021 Jan 7.
2
Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study.基于贝叶斯网络模型的子宫内膜癌术前风险分层(ENDORISK):一项开发和验证研究。
PLoS Med. 2020 May 15;17(5):e1003111. doi: 10.1371/journal.pmed.1003111. eCollection 2020 May.
3
Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer.
年轻患者有资格行保守治疗的子宫内膜癌的淋巴结转移概率。
Gynecol Oncol. 2020 Apr;157(1):131-135. doi: 10.1016/j.ygyno.2020.02.021. Epub 2020 Mar 3.
4
Correlation between pre-operative and final histological diagnosis on endometrial cancer.子宫内膜癌术前与最终组织学诊断的相关性。
Int J Gynecol Cancer. 2019 Jun;29(5):886-889. doi: 10.1136/ijgc-2018-000041. Epub 2019 Jan 4.
5
The prognostic significance of estrogen and progesterone receptors in grade I and II endometrioid endometrial adenocarcinoma: hormone receptors in risk stratification.I 级和 II 级子宫内膜样腺癌中雌激素和孕激素受体的预后意义:激素受体在风险分层中的作用。
J Gynecol Oncol. 2019 Jan;30(1):e13. doi: 10.3802/jgo.2019.30.e13. Epub 2018 Oct 29.
6
Is there a benefit of lymphadenectomy for overall and recurrence-free survival in type I FIGO IB G1-2 endometrial carcinoma? A retrospective population-based cohort analysis.对于Ⅰ型国际妇产科联盟(FIGO)ⅠB G1-2 期子宫内膜癌患者,淋巴结切除术是否能提高总生存率和无复发生存率?一项基于人群的回顾性队列分析。
J Cancer Res Clin Oncol. 2018 Oct;144(10):2019-2027. doi: 10.1007/s00432-018-2715-4. Epub 2018 Jul 23.
7
Tumor Grade Correlation Between Preoperative Biopsy and Final Surgical Specimen in Endometrial Cancer: The Use of Different Diagnostic Methods and Analysis of Associated Factors.子宫内膜癌术前活检与最终手术标本肿瘤分级的相关性:不同诊断方法的应用及相关因素分析。
Int J Gynecol Cancer. 2018 Sep;28(7):1258-1263. doi: 10.1097/IGC.0000000000001304.
8
ER and PR expression and survival after endometrial cancer.子宫内膜癌的 ER 和 PR 表达与生存。
Gynecol Oncol. 2018 Feb;148(2):258-266. doi: 10.1016/j.ygyno.2017.11.027. Epub 2017 Dec 6.
9
Role of lymphadenectomy in intermediate-risk endometrial cancer: a matched-pair study.淋巴结切除术在中危子宫内膜癌中的作用:一项配对研究。
J Gynecol Oncol. 2018 Jan;29(1):e1. doi: 10.3802/jgo.2018.29.e1.
10
Survival benefit of pelvic and paraaortic lymphadenectomy in high-grade endometrial carcinoma: a retrospective population-based cohort analysis.盆腔及腹主动脉旁淋巴结切除术对高级别子宫内膜癌的生存获益:一项基于人群的回顾性队列分析。
J Cancer Res Clin Oncol. 2017 Dec;143(12):2555-2562. doi: 10.1007/s00432-017-2508-1. Epub 2017 Aug 24.